Maxalt Rapitab (Rizatriptan Benzoate)

Rizatriptan binds selectively to serotonin 5‑HT1B and 5‑HT1D receptors located on cranial blood vessels and trigeminal nerve endings. This action causes vasoconstriction of dilated intracranial vessels and blocks the release of pain‑triggering neuropeptides, interrupting the migraine cascade.

The specific dose of Maxalt Rapitab is determined by the prescribing healthcare professional based on the individual’s medical condition, severity of migraine, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for rizatriptan in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against possible risks before prescribing to pregnant or nursing women, and discuss alternative options when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with other triptans, rizatriptan offers a rapid onset of action and is effective for many patients with both migraine with and without aura. Its safety profile is similar to other agents in the class, but individual response and tolerability can vary, so clinicians may choose based on patient history and preference.

Store Maxalt Rapitab below 25 °C in its original packaging, protecting it from moisture, heat, and direct sunlight. Do not store in bathrooms or near kitchen appliances where temperature fluctuations are common.

Maxalt Rapitab is taken orally, usually with a glass of water. It should be swallowed whole and not crushed or chewed. The medication is intended for use at the onset of migraine symptoms, and a second dose may be considered only after a specified interval if needed, as directed by a healthcare professional.

Serious risks include chest pain or coronary vasospasm, which may indicate cardiac ischemia, and serotonin syndrome when combined with other serotonergic drugs. Patients should seek immediate medical attention if they experience severe chest discomfort, shortness of breath, or signs of serotonin excess such as agitation, fever, or rapid heart rate.

Patients with a history of coronary artery disease, uncontrolled hypertension, severe hepatic impairment, or those taking MAO inhibitors, other triptans, or ergot derivatives should avoid Maxalt Rapitab. Additionally, individuals with known hypersensitivity to rizatriptan or any excipients in the formulation should not use the product.